Christopher Robison, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 120 N 7th St Ste 200, Chambersburg, PA 17201 Phone: 717-217-6803 Fax: 717-217-6824 |
Ashish Behari, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 120 N 7th St, Chambersburg, PA 17201 Phone: 717-217-6803 Fax: 717-217-6824 |
Amy S Burns, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 761 5th Ave Ste D, Chambersburg, PA 17201 Phone: 717-988-0090 Fax: 717-221-5320 |
Louis L Glass, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 120 N 7th St Ste 200, Chambersburg, PA 17201 Phone: 717-217-6803 Fax: 717-217-6824 |
Virgilio A Centenera, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 120 N 7th St Ste 200, Chambersburg, PA 17201 Phone: 717-217-6803 Fax: 717-217-6824 |
News Archive
Despite one in 10 people worldwide having chronic kidney disease, a new global report - The Global Kidney Health Atlas - presented at this week's World Congress of Nephrology in Mexico City and compiled by the International Society of Nephrology and kidney health experts worldwide and published in JAMA- highlights the huge gaps in kidney disease care and prevention in both developed and developing countries, with many countries not prioritising kidney health.
Results of a major trial of hormone therapy on men with locally advanced prostate cancer announced today were a significant development and would be welcomed by patients and oncologists world-wide, according to The Cancer Council Australia.
Inflammatory processes occur in the brain in conjunction with stroke and neurological diseases such as Alzheimer's and Parkinson's disease. Researchers from Lund University and Karolinska Institutet in Sweden, in close cooperation with a group led by Professor José L. Venero at the University of Seville, have presented new findings about some of the 'key players' in inflammation.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.
› Verified 8 days ago